Surrozen, Inc. SRZN
At closeNov 6, 2026, 4:42 PM EST
After hours · Nov 6, 4:42 PM ET
- YTD
- +37.17%
- 1 year
- +148.00%
- Market cap
- 542.35M
- Revenue (ttm)
- 10.00M
- EPS (ttm)
- -39.08
- Shares out
- 3.25M
- Forward P/E
- -2.75
- YTD return
- +37.17%
- 1-year return
- +148.00%
- Volume
- 140.73K
- Avg volume
- 543.11K
- Open
- 29.02
- Previous close
- 29.00
- Day's range
- 29.00 – 31.23
- 52-week range
- 11.51 – 37.83
- Price target
- 33.00 (+6.5%)
- Earnings date
- Aug 12, 2024
1M +5.85 (+23.26%)
Key statistics
- Enterprise value
- 4.62M
- PEG ratio
- 0.00
- Price / sales
- 3.97
- Price / book
- 6.96
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 31.01M
- Total debt
- 1.53M
- Return on equity
- -173.59%
- Short % of float
- 1.40%
- 50-day average
- 10.18
- 200-day average
- 10.09
Analyst view
- Strong buy0
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 12, 2024
Expected Aug 12, 2024. Consensus EPS estimate -2.64.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -2.77 | -0.44 | +2.33 | +84.12% |
| Aug 12, 2024 | Jun 1, 2024 | -2.79 | — | — | — |
| Aug 12, 2024 | Jun 1, 2024 | -2.79 | -1.54 | +1.25 | +44.80% |
| May 8, 2024 | Mar 1, 2024 | -4.25 | -4.24 | +0.01 | +0.24% |
| May 8, 2024 | Mar 1, 2024 | -4.25 | — | — | — |
| Apr 3, 2024 | Dec 1, 2023 | -4.35 | — | — | — |
About Surrozen, Inc.
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- surrozen.com
News
Scholastic Posts Downbeat Q1 Results, Joins Legacy Education, Zscaler And Other Big Stocks Moving Lower In Friday’s Pre-Market Session 
HC Wainwright & Co. Maintains Buy on Surrozen, Raises Price Target to $54 
Why INLIF Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket 
12 Health Care Stocks Moving In Thursday's Intraday Session 
Crude Oil Rises Over 4%; Darden Earnings Miss Views 
Surrozen Gains Momentum as FDA Submission Opens Path for Lead Therapy 
Dow Tumbles Over 100 Points; US Jobless Claims Fall to 197,000 
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
Surrozen Submits IND Application To FDA Seeking To Evaluate SZN-8141, Bifunctional Wnt Agonist And Vascular Endothelial Growth Factor Antagonist Antibody, For Treatment Of Diabetic Macular Edema 
HC Wainwright & Co. Reiterates Buy on Surrozen, Maintains $44 Price Target
Your note
Sign in to keep a note on SRZN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COLUMN GROUP III GP, L.P | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 3, 2024 | 0 |
| KUTZKEY TIM PH.D. | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 3, 2024 | 0 |
| LI YANG | Officer | Stock Award(Grant) | Jun 13, 2024 | 10,888 |
| PARKER CRAIG C | Chief Executive Officer | Stock Award(Grant) | Jun 13, 2024 | 5,824 |
| WILLIAMS CHARLES O | Chief Operating Officer | Stock Award(Grant) | Jun 13, 2024 | 5,863 |
| YEH WEN-CHEN M.D., PH.D. | Officer | Stock Award(Grant) | Jun 14, 2023 | 27,216 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Column Group LLC | 24.93% | 810,088 | 9.91M | Sep 29, 2024 |
| RA Capital Management, L.P. | 8.70% | 282,580 | 3.46M | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 5.76% | 187,206 | 2.29M | Sep 29, 2024 |
| Stempoint Capital LP | 5.63% | 182,918 | 2.24M | Sep 29, 2024 |
| Armistice Capital, LLC | 4.28% | 139,000 | 1.70M | Sep 29, 2024 |
| Stonepine Capital Management, LLC | 3.38% | 110,000 | 1.35M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.43% | 46,578 | 569.65K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.56% | 18,127 | 221.69K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.34% | 10,983 | 134.32K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.16% | 5,269 | 64.44K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.08% | 2,745 | 33.57K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.08% | 2,592 | 31.70K | Oct 30, 2024 |